Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder - a single Photon Emission Computed Tomography with [Tc99m]TRODAT-1 study

NeuroImage

Volumn 40, Issue 3, 2008, Pages 1195-1201

  Szobot, Claudia M ^a,b,c   Shih, Ming Chi ^d   Schaefer, Thais ^c   Júnior, Neivo ^e   Hoexter, Marcelo Q ^d   Fu, Ying Kai ^f   Pechansky, Flávio ^b   Bressan, Rodrigo A ^d   Rohde, Luis A P ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e POA ^*  (Brazil)

^f INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Adolescents; Attention Deficit Hyperactivity Disorder; Dopamine transporter; Methylphenidate; SPECT; Substance Use Disorders

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED DRUG RELEASE; DRUG PROTEIN BINDING; HUMAN; MALE; MORNING DOSAGE; NEUROIMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANCE ABUSE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHEMISTRY, PHARMACEUTICAL; DATA INTERPRETATION, STATISTICAL; DIAGNOSIS, DUAL (PSYCHIATRY); DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; METHYLPHENIDATE; NEOSTRIATUM; ORGANOTECHNETIUM COMPOUNDS; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 40849117957     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2007.12.050     Document Type: Article

References (58)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition (1994), American Psychiatric Association, Washington, DC
2. Amorim P. Mini International Neuropsychiatric Interview (MINI): Validação de entrevista breve para diagnóstico de transtornos mentais. Revista Bras. Psiquiatr. 22 (2000) 106-115
3. Associação Brasileira de Empresas de Pesquisas. Critério de Classificação Econômica Brasil (2005). http://www.anep.org.br/codigosguias/CCEP.pdf Available at http://www.anep.org.br/codigosguias/CCEP.pdf (assessed April 18, 2005)
4. Badanich K.A., Adler K.J., and Kirstein C.L. Adolescents differ from adults in cocaine conditioned place preference and cocaine-induced dopamine in the nucleus accumbens septi. Eur. J. Pharmacol. 550 1-3 (2006) 95-106 (21)
5. Biederman J., Monuteaux M.C., Mick E., Spencer T., Wilens T.E., Silva J.M., Snyder L.E., and Faraone S.V. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol. Med. 36 2 (2006) 167-179
6. Bressan R.A., Shih M.C., Hoexter M.Q., and Lacerda A.L. Can molecular imaging techniques identify biomarkers for neuropsychiatric disorders?. Rev. Bras. Psiquiatr. 29 2 (2007) 102-104
7. Carpentier P.J., de Jong C.A., Dijkstra B.A., Verbrugge C.A., and Krabbe P.F. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100 12 (2005) 1868-1874
8. Choi S.R., Kung M.P., Plossl K., Meegalla S., and Kung H.F. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nucl. Med. Biol. 26 (1999) 461-466
9. Cowell R.M., Kantor L., Hewlett G.H., Frey K.A., and Gnegy M.E. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389 1 (2000) 59-65
10. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., and Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290 5 (2002) 1545-1550 (8)
11. DeMilio L. Psychiatric syndromes in adolescent substance abusers. Am. J. Psychiatry 46 9 (1989) 1212-1214
12. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., and Fischman A.J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354 9196 (1999) 2132-2133 18-25
13. Dresel S., Krause J., Krause K.H., LaFougere C., Brinkbaumer K., Kung H.F., and Tatsch K. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur. J. Nucl. Med. 27 10 (2000) 1518-1524
14. Ercan E.S., Coskunol H., Varan A., and Toksoz K. Childhood attention deficit/hyperactivity disorder and alcohol dependence: a 1-year follow-up. Alcohol Alcohol. 38 4 (2003) 352-356
15. Erixon-Lindroth N., Farde L., Wahlin T.B., Sovago J., Halldin C., and Bäckman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 138 1 (2005) 1-12 (30)
16. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., and Caron M.G. Role of serotonin in the paradoxical calming effect os psychoestimulants on hyperactivity. Science 283 (1999) 397-401
17. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87 5 (1990) 1932-1936
18. Horner B.R., and Scheibe K.E. Prevalence and implications of attention-deficit hyperactivity disorder among adolescents in treatment for substance abuse. J. Am. Acad. Child Adolesc. Psych. 36 1 (1997) 30-36
19. Jucaite A., Fernell E., Halldin C., Forssberg H., and Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol. Psychiatry 57 3 (2005) 229-238 (1)
20. Koob G.F. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 101 Suppl 1 (2006) 23-30
21. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 5335 (1997) 52-58
22. Krain A.L., and Castellanos F.X. Brain development and ADHD. Clin. Psychol. Rev. 26 4 (2006) 433-444
23. Krause K.H., Dresel S.H., Krause J., Kung H.F., and Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 285 2 (2000) 107-110 (12)
24. Krause K.H., Dresel S.H., Krause J., Kung H.F., Tatsch K., and Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 5 2 (2002) 111-113
25. Krause J., la Fougere C., Krause K.H., Ackenheil M., and Dresel S.H. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur. Arch. Psychiatry Clin. Neurosci. 255 6 (2005) 428-431
26. Kuperman S., Schlosser S.S., Kramer J.R., Bucholz K., Hesselbrock V., Reich T., and Reich W. Developmental sequence from disruptive behavior diagnosis to adolescent alcohol dependence. Am. J. Psychiatry 158 12 (2001) 2022-2026
27. la Fougère C., Krause J., Krause K.H., Josef G.F., Hacker M., Koch W., Hahn K., Tatsch K., and Dresel S. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl. Med. Commun. 27 9 (2006) 733-737
28. Larisch R., Sitte W., Antke C., Nikolaus S., Franz M., Tress W., and Muller H.W. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl. Med. Commun. 27 3 (2006) 267-270
29. Letchworth S.R., Nader M.A., Smith H.R., Friedman D.P., and Porrino L.J. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J. Neurosci. 21 8 (2001) 2799-2807 (5)
30. Levin F.R., Evans S.M., Brooks D.J., Kalbag A.S., Garawi F., and Nunes E.V. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 81 2 (2006) 137-148
31. Levin F.R., Evans S.M., Brooks D.J., and Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 87 1 (2007) 20-29
32. Liu F., Muniz R., Minami H., and Silva R.R. Review and comparison of the long acting methylphenidate preparations. Psychiatr. Q. 76 3 (2005) 259-269
33. Mattos P., Serra Pinheiro M.A., Rohde L.A., and Pinto D. A Brazilian version of the MTA-SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and oppositional-defiant disorder. Rev. Psiquiatr. Rio Gd. Sul. 28 3 (2006) 290-297
34. o edição. São Paulo, SP: Protoc - Hospital das Clínicas da FMUSP (1995)
35. Molina B.S.G.M., Smith B.H., and Pelham W.E. Interactive effects of Attention Deficit Hyperactivity Disorder and Conduct Disorder on early adolescent substance use. Psychol. Addict. Behav. 13 (1999) 348-358
36. Pliszka S.R., Crismon M.L., Hughes C.W., Corners C.K., Emslie G.J., Jensen P.S., McCracken J.T., Swanson J.M., and Lopez M. Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psych. 45 6 (2006) 642-657
37. Polanczyk G., Horta B., Lima M., Biederman J., and Rohde L.A. The worldwide prevalence of ADHD. A systematic review and meta-regression analysis. Am. J. Psychiatry 164 6 (2007) 942-948
38. Price D.A., Owens W.A., Gould G.G., Frazer A., Roberts J.L., Daws L.C., and Giuffrida A. CB(1)-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J. Neurochem. 101 2 (2007) 389-396
39. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., and Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 40 1 (2005) 2-14
40. Rohde L.A., Szobot C., Polanczyk G., Schmitz M., Martins S., and Tramontina S. Attention-deficit/hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder?. Biol. Psychiatry 57 11 (2005) 1436-1441 (1)
41. Schlaepfer T.E., Pearlson G.D., Wong D.F., Marenco S., and Dannals R.F. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. Am. J. Psychiatry 154 9 (1997) 1209-1213
42. Shaffer D., Gould M.S., Brasic J., Ambrosini P., Fisher P., Bird H., and Aluwahlia S. A children's global assessment scale (CGAS). Arch. Gen. Psychiatry 40 (1983) 1228-1231
43. Spencer T.J., Biederman J., Ciccone P.E., Madras B.K., Dougherty D.D., Bonab A.A., Livni E., Parasrampuria D.A., and Fischman A.J. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 163 3 (2006) 387-395
44. Spencer T.J., Biederman J., and Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Ambul. Pediatr. 7 1 Suppl (2007) 73-81
45. Stansfield K.H., and Kirstein C.L. Neurochemical effects of cocaine in adolescence compared to adulthood. Brain Res. Dev. Brain Res. 159 2 (2005) 119-125 (6)
46. Swanson J.M., Kraemer H.C., Hinshaw S.P., Arnold L.E., Conners C.K., Abikoff H.B., Clevenger W., Davies M., Elliott G.R., Greenhill L.L., Hechtman L., Hoza B., Jensen P.S., March J.S., Newcorn J.H., Owens E.B., Pelham W.E., Schiller E., Severe J.B., Simpson S., Vitiello B., Wells K., Wigal T., and Wu M. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J. Am. Acad. Child Adolesc. Psych. 40 2 (2001) 168-179
47. Szobot C., Rohde L.A., Bukstein O., Molina B.S.G., Martins C., Ruaro P., and Pechansky F. Is Attention-Deficit/ Hyperactivity Disorder associated with illicit Substance Use Disorders in male adolescents? A community-based case-control study. Addiction 102 7 (2007) 1122-1130
48. Szobot, C.M., Rohde, L.A., Katz, B., Ruaro, P., Schaefer, T., Walcher, M., Bukstein, O., Pechansky, F., in press. A randomized crossover clinical study showing that methylphenidate-SODAS improves Attention-Deficit/ Hyperactivity Disorder symptoms in adolescents with Substance Use Disorder. Braz. J. Med. Biol. Res.
49. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., and Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59 6 (2006) 508-515 (15)
50. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52 6 (1995) 456-463
51. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155 10 (1998) 1325-1331
52. Volkow N.D., Fowler J.S., and Wang G.J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47 Suppl 1 (2004) 3-13
53. Volkow N.D., Wang G.J., Fowler J.S., Telang F., Maynard L., Logan J., Gatley S.J., Pappas N., Wong C., Vaska P., Zhu W., and Swanson J.M. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry 161 7 (2004) 1173-1180
54. Volkow N.D., Wang G.J., Newcorn J., Fowler J.S., Telang F., Solanto M.V., Logan J., Wong C., Ma Y., Swanson J.M., Schulz K., and Pradhan K. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34 3 (2007) 1182-1190 (1)
55. Wechsler D. WISC-III/Manual (1991), The Psychological Corporation, New York, NY
56. Wechsler D. Manual of the Wechsler Adult Intelligence Scale. 3rd edition (1997), The Psychological Corporation, San Antonio TX
57. White A.M., Jordan J.D., Schroeder K.M., Acheson S.K., Georgi B.D., Sauls G., Ellington R.R., and Swartzwelder H.S. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. Subst. Abuse 25 1 (2004) 53-59
58. World Health Organization (WHO), 2006. Available at http://www.who.int/substance_abuse/facts/cannabis/en/index.html (assessed January 08, 2006).